<DOC>
	<DOCNO>NCT02292173</DOCNO>
	<brief_summary>The main purpose study see whether combination trametinib sorafenib help people hepatocellular cancer . Researchers also want find combination trametinib sorafenib safe tolerable .</brief_summary>
	<brief_title>Trametinib Combination With Sorafenib Patients With Advanced Hepatocellular Cancer</brief_title>
	<detailed_description>Each cycle last 4 week . Sorafenib trametinib administer orally continuous basis . During first cycle sorafenib start day 1 trametinib day 8 improve tolerance . Participants get restaging scan every 2 cycle . Participants continue receive treatment stable disease well response Response Evaluation Criteria Solid Tumors ( RECIST ) criteria 1.1 .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Must radiographic histological diagnosis hepatocellular cancer ( HCC ) , advanced stage disease amenable curative surgical resection . Potential participant without histologic diagnosis must meet radiographic criterion HCC . Child Pugh score must 5 6 ( Child Pugh Class A ) Must measurable disease RECIST criteria 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status ≤1 Must normal organ marrow function Female participant childbearing potential must agree use dual method contraception negative serum pregnancy test screening , male participant must use effective barrier method contraception sexually active female childbearing potential . For male female participant , effective method contraception must use throughout study four month follow last dose . Able swallow retain orally administer medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel Participants dose expansion part must tumor amenable biopsy . Ability understand willingness sign write informed consent document Have receive radiation therapy , major surgery , locoregional therapy , within 4 week prior first dose study drug All prior treatmentrelated toxicity must ≤ Grade 1 . Have receive sorafenib systemic therapy treatment HCC past Any serious and/or unstable preexist medical disorder ( aside malignancy exception ) , psychiatric disorder , condition could interfere participant 's safety , obtain informed consent compliance study procedure History evidence cardiovascular risk Known history human immunodeficiency virus ( HIV ) positivity History retinal vein occlusion ( RVO ) Symptomatic untreated leptomeningeal brain metastasis spinal cord compression History interstitial lung disease pneumonitis Are pregnant lactate Any underlying condition would significantly interfere absorption oral medication History another active malignancy last 3 year . Exception : Potential participant diseasefree 3 year , history completely resect nonmelanoma skin cancer and/or potential participant indolent second malignancy eligible . Uncontrolled infection require parenteral antibiotic , antiviral , antifungal within one week prior first dose ; patient control infection prophylactic antibiotic permit study Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug , excipients dimethyl sulfoxide Concurrent therapy approve investigational anticancer therapy Concomitant use strong Cytochrome P450 3A4 ( CYP3A4 ) inducer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Liver Neoplasms</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Advanced</keyword>
	<keyword>Mitogen-Activated Protein Kinase ( MEK ) Inhibitor</keyword>
	<keyword>Kinase Inhibitor</keyword>
</DOC>